
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/118168/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Performance of VivaDiag COVIDâ€19 IgM/IgG Rapid Test is inadequate for diagnosis of COVIDâ€19 in acute patients referring to emergency room department. Journal of Medical Virology, 2020, 92, 1724-1727.	2.5	205
2	Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. Lancet Infectious Diseases, The, 2021, 21, e112.	4.6	138
3	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clinical Microbiology and Infection, 2020, 26, 1094.e1-1094.e5.	2.8	121
4	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Eurosurveillance, 2020, 25, .	3.9	119
5	Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitorsâ ță ță ță î Atherosclerosis, 2002, 162, 433-438.	0.4	114
6	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica, 2020, 105, 2834-2840.	1.7	114
7	The Incidence and Spectrum of AIDSâ€Defining Illnesses in Persons Treated with Antiretroviral Drugs. Clinical Infectious Diseases, 1998, 27, 1379-1385.	2.9	102
8	SARS Cov-2 infection in a renal-transplanted patient: A case report. American Journal of Transplantation, 2020, 20, 1882-1884.	2.6	76
9	Structured treatment interruptions to control HIV-1 infection. Lancet, The, 2000, 355, 287-288.	6.3	72
10	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clinical Microbiology and Infection, 2018, 24, 546.e1-546.e8.	2.8	67
11	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. International Journal of Infectious Diseases, 2021, 104, 315-319.	1.5	66
12	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	1.3	56
13	Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Medicine, 2005, 6, 145-150.	1.0	54
14	Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. British Journal of Clinical Pharmacology, 1999, 48, 712-715.	1.1	53
15	The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1920-1925.	1.1	53
16	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. Journal of Hospital Infection, 2020, 105, 474-476.	1.4	51
17	Emergency Department and Out-of-Hospital Emergency System (112—AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. Internal and Emergency Medicine, 2020, 15, 825-833.	1.0	50
18	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms, 2020, 8, 977.	1.6	41

#	Article	IF	CITATIONS
19	Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. Internal and Emergency Medicine, 2020, 15, 819-824.	1.0	41
20	Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naĀ-ve patients with undetectable viraemia. Aids, 2000, 14, 109-116.	1.0	38
21	Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals. Aids, 2004, 18, 859-869.	1.0	36
22	Etravirine for the treatment of HIV infection. Expert Review of Anti-Infective Therapy, 2008, 6, 427-433.	2.0	34
23	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Internal and Emergency Medicine, 2020, 15, 1457-1465.	1.0	32
24	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. Journal of Hospital Infection, 2020, 105, 477-479.	1.4	31
25	High-Performance Liquid Chromatography Method for Analyzing the Antiretroviral Agent Efavirenz in Human Plasma. Therapeutic Drug Monitoring, 1999, 21, 346.	1.0	31
26	Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clinical Trials, 2002, 3, 115-124.	2.0	30
27	Adoptive Transfer of <scp>JC</scp> Virusâ€Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy. Annals of Neurology, 2021, 89, 769-779.	2.8	30
28	Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Doseâ€Ranging Study Involving Treatmentâ€Experienced Patients with HIVâ€1 Infection. Clinical Infectious Diseases, 2008, 47, 969-978.	2.9	29
29	Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clinical Infectious Diseases, 2019, 69, 1731-1739.	2.9	29
30	Hydroxyurea and Didanosine Long-Term Treatment Prevents HIV Breakthrough and Normalizes Immune Parameters. AIDS Research and Human Retroviruses, 1999, 15, 1333-1338.	0.5	27
31	Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. Journal of Clinical Virology, 2003, 26, 95-100.	1.6	23
32	Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2005, 56, 790-792.	1.3	23
33	Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting. BMC Public Health, 2013, 13, 981.	1.2	23
34	High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. Aids, 1999, 13, 870.	1.0	22
35	Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE). Scientific Reports, 2021, 11, 1137.	1.6	22
36	Efavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1–Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 453.	0.9	21

#	Article	IF	CITATIONS
37	Sex differences in nevirapine disposition in HIV-infected patients. Aids, 2003, 17, 2399-2400.	1.0	21
38	Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation. BMC Pulmonary Medicine, 2020, 20, 109.	0.8	20
39	Hepatitis C Infection Influence on Immune Recovery in HIV-Positive Patients on Successful HAART: The Role of Genotype 3. Current HIV Research, 2010, 8, 186-193.	0.2	19
40	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Journal of Medical Virology, 2014, 86, 1648-1655.	2.5	19
41	Efavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1–Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 453.	0.9	18
42	Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease. Infection, 2015, 43, 561-567.	2.3	17
43	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. American Journal of Transplantation, 2020, 20, 1629-1641.	2.6	17
44	Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. Aids, 2002, 16, 1767-1773.	1.0	16
45	Predicting the magnitude of short-term CD4 <sup>+</sup> T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 165-175.	0.6	16
46	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. Journal of Antimicrobial Chemotherapy, 2007, 60, 831-836.	1.3	15
47	Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2000, 45, 343-347.	1.3	13
48	Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV–hepatitis C virus co-infection. Aids, 2004, 18, 123-127.	1.0	13
49	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. Aids, 2003, 17, 2669-2671.	1.0	12
50	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. European Journal of Clinical Pharmacology, 2005, 61, 545-549.	0.8	12
51	Post-exposure rate of tuberculosis infection among health care workers measured with tuberculin skin test conversion after unprotected exposure to patients with pulmonary tuberculosis: 6-year experience in an Italian teaching hospital. BMC Infectious Diseases, 2014, 14, 324.	1.3	11
52	Prosthetic Joint Infection from Carbapenemase-Resistant Klebsiella pneumoniae Successfully Treated with Ceftazidime-Avibactam. Case Reports in Infectious Diseases, 2018, 2018, 1-5.	0.2	11
53	QTc Interval and Mortality in a Population of SARS-2-CoV Infected Patients. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008890.	2.1	11
54	Efficacy of βâ€lactam/βâ€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing <i>Enterobacterales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€6OT Project). Transplant Infectious Disease, 2021, 23, e13520.	0.7	10

#	Article	IF	CITATIONS
55	Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients. Viruses, 2021, 13, 2261.	1.5	10
56	Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients. Vaccine Journal, 2002, 9, 1114-1118.	3.2	9
57	Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. Microorganisms, 2021, 9, 2622.	1.6	9
58	CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS Reviews, 2008, 10, 236-44.	0.5	9
59	Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 192-195.	0.9	8
60	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. Clinical Microbiology and Infection, 2019, 25, 1443-1446.	2.8	8
61	Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. Internal and Emergency Medicine, 2021, 16, 1141-1152.	1.0	8
62	Nelfinavir Suspension Obtained from Nelfinavir Tablets Has Equivalent Pharmacokinetic Profile. Journal of Chemotherapy, 2001, 13, 569-574.	0.7	7
63	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. Aids, 2004, 18, 2205-2208.	1.0	7
64	Running out of bullets: The challenging management of acute hepatitis and SARS OVâ€2 from the SMatteo COvid19 Registry (SMACORE). Liver International, 2020, 40, 2655-2659.	1.9	7
65	Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays. Journal of Clinical Microbiology, 1998, 36, 3369-3371.	1.8	7
66	Infective endocarditis in patients with hepatic diseases. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 279-284.	1.3	6
67	The role of qSOFA compared to other prognostic scores in septic patients upon admission to the emergency department. European Journal of Internal Medicine, 2018, 53, e11-e13.	1.0	6
68	What prompts clinicians to start antibiotic treatment in COVID-19 patients? An Italian web survey helps us to understand where the doubts lie. Journal of Global Antimicrobial Resistance, 2021, 26, 74-76.	0.9	6
69	Colitis in an elderly immunocompetent patient. Journal of Clinical Virology, 2012, 55, 187-190.	1.6	5
70	Tuberculosis-induced haemophagocytic syndrome in a patient on haemodialysis treated with anti-thymocyte globulin [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 248-249.	0.6	5
71	Evaluation of a model to improve collection of blood cultures in patients with sepsis in the emergency room. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 241-246.	1.3	5
72	Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017. Clinical Microbiology and Infection, 2019, 25, 526-528.	2.8	5

#	Article	IF	CITATIONS
73	Redistribution of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors after a Protease Inhibitor-Sparing Regimen. AIDS Research and Human Retroviruses, 2005, 21, 545-554.	0.5	4
74	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. Journal of Clinical Virology, 2010, 47, 253-257.	1.6	4
75	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. Clinical Microbiology and Infection, 2020, 26, 1569-1571.	2.8	4
76	Detection of the SARSâ€CoVâ€2 in different biologic specimens from positive patients with COVIDâ€19, in Northern Italy. Pediatric Allergy and Immunology, 2020, 31, 72-74.	1.1	4
77	Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens. Current HIV Research, 2008, 6, 70-76.	0.2	3
78	A Case Report of Disseminated Histoplasmosis in AIDS Diagnosed Through Peripheral Blood Smear. Current HIV Research, 2021, 19, 457-459.	0.2	3
79	QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. Journal of Cardiovascular Medicine, 2022, 23, e21-e23.	0.6	3
80	Minimally invasive procedure for removal of infected ventriculoatrial shunts. Acta Neurochirurgica, 2021, 163, 455-462.	0.9	3
81	Epidemiology of Mycobacterium tuberculosis infection in Pavia province, Lombardy, Northern Italy, 1998-2013. New Microbiologica, 2016, 39, 264-268.	0.1	3
82	Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities. International Journal of STD and AIDS, 2012, 23, 837-842.	0.5	2
83	Aetiology and outcome of pneumoniae in HIV-positive patients in the antiretroviral era. Infectious Diseases, 2017, 49, 225-228.	1.4	2
84	Migrations do not modify Mycobacterium tuberculosis resistance rates: a 20-year retrospective study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1083-1087.	1.3	2
85	Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. Current HIV Research, 2009, 7, 425-433.	0.2	1
86	Response to Antiretroviral Treatment After Failure of NNRTI Plus NRTIs-Based Therapy. Data from the ARCA Collaborative Group. Current HIV Research, 2012, 10, 334-340.	0.2	1
87	Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 547-554.	0.6	1
88	Mitral Valve Infective Endocarditis due to Streptococcus pyogenes: A Case Report. Cureus, 2019, 11, e4461.	0.2	1
89	Immunosuppressive Treatment Does Not Prevent Humoral and Cellular Virus-Specific Immunity in Heart or Lung Recipients with SARS-CoV-2 Pneumonia. Journal of Heart and Lung Transplantation, 2021, 40, S145.	0.3	0